Multiplexed protein profiling after aneurysmal subarachnoid hemorrhage: Characterization of differential expression patterns in cerebral vasospasm

Abstract

Cerebral vasospasm is major contributor to delayed morbidity following aneurysmal subarachnoid hemorrhage. We sought to evaluate differential plasma protein levels across time in patients with aneurysmal subarachnoid hemorrhage to identify potential biomarkers and to better understand the pathogenesis of cerebral vasospasm. Nine female patients with aneurysmal subarachnoid hemorrhage underwent serial analysis of 239 different serum protein levels using quantitative, multiplexed immunoassays (DiscoveryMAP 250+ v2.0, Mryiad RBM, Austin, TX USA) on post-hemorrhage days 0 and 5. A repeated measures analysis of variance determined that mean protein concentration decreased significantly in patients who developed vasospasm versus those who did not for alpha-2-macroglobulin (F [1.00, 7.00] = 16.33, p = 0.005), angiogenin (F [1.00, 7.00] = 7.65, p = 0.028), apolipoprotein A-IV (F [1.00, 7.00] = 6.308, p = 0.040), granulocyte colony-stimulating factor (F [1.00, 7.00] = 9.08, p = 0.020), macrophage-stimulating protein (F [1.00, 7.00] = 24.21, p = 0.002), tetranectin (F [1.00, 7.00] = 5.46, p < 0.039), vascular endothelial growth factor receptor 3 (F [1.00, 7.00] = 6.94, p = 0.034), and significantly increased for vitronectin (F [1.00, 7.00] = 5.79, p = 0.047). These biomarkers may be of value in detecting cerebral vasospasm, possibly aiding in the identification of patients at high-risk prior to neurological deterioration.

Feasibility of investigating differential proteomic expression in depression: implications for biomarker development in mood disorders

“… 19 , 20 The current platform, based initially on pharmaceutical and biotechnological opportunities, focused on immune mediator and cytokine quantification for drug development has continued to expand and now includes 320 proteins (see Supplementary eTable 1 ). 21 , 22 , 23 These same inflammatory and immune mediated biomarkers are increasingly recognized in the underlying neurobiology of mood disorders. 7 , 8 , 9 , 10 , 11 , 12 …”

CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease

“…Concentrations of 190 proteins were quantified in the Validation cohort using the RBM Human Discovery Map v 1.0 platform 28 . RBM provided data for the healthy control 2.5th and 97.5th percentiles, representing the low and high ends of the normal range, which was reportedly based on approximately 100 healthy individuals.…”